The Clinical Trials Working Group: NCI panel considers plan to centralize clinical trial review and prioritization. NCI director faults system for duplication, “equivocal results.”
Blueprint Group co-chairman Mark Ratain says group seeks “the perfect peer review system,” but a member’s email questions the proposal.
Cooperative group chairman suggest changes to incentive system.
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish - The Galleri MCD vote: What FDA asked its advisors to ignore
- FDA advisory committee votes in favor of Galleri approval, but calls for removal of “early” detection claims
Clinical benefit will not be considered for approval, FDA says - Trump weighs—and abandons—an executive order that would give OMB veto power over NIH grants
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma









